Microbix sues Novartis for patent infringement in Europe

Canada-based Microbix has slapped Novartis ($NVS) with a lawsuit in Europe, where it says the Swiss pharma giant has infringed its patent on Virusmax--a technology used for increasing virus yields in egg-based vaccine manufacturing. The latest litigation is part of an ongoing legal tussle between the two companies: According to Microbix, Novartis has previously challenged its IP shield and is appealing a January decision from the European Patent Office that Virusmax is a novel, useful and nonobvious invention. A Novartis spokeswoman told FierceVaccines the Basel-based drugmaker could not comment. Release

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.